Trial Profile
A Study on Predictors of Treatment Response to daclatasvir and Asunaprevir combination therapy in Patients with genotype 1 Chronic Hepatitis C Virus Infection
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Jun 2019
Price :
$35
*
At a glance
- Drugs Asunaprevir (Primary) ; Daclatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 24 Jun 2019 Status changed from recruiting to completed.
- 24 May 2016 New trial record